New publication (ACCEPTED): Rational Design of Apoptosis Signal-Regulating Kinase 1 Inhibitors: Discovering Novel Structural Scaffold

Otava's manuscript on new ASK1 inhibitors has been accepted for publcation in European Journal of Medicinal Chemistry

Abstract: Increased activity of apoptosis signal-regulating kinase 1 (ASK1) is associated with a number of human disorders and the inhibitors of ASK1 may become important compounds for pharmaceutical application. Here we report novel ASK1 inhibitor scaffold, namely 5-(5-Phenyl-furan-2-ylmethylene)-2-thioxo-thiazolidin-4-one, that has been identified using virtual screening and biochemical tests.

New publication (ACCEPTED): Discovery of New Scaffolds for Rational Design of HCV NS5B Polymerase Inhibitors

Otava's manuscript on new HCV NS5B Polymerase Inhibitors has been accepted for publcation in European Journal of Medicinal Chemistry

Abstract: Hepatitis C virus (HCV) NS5B polymerase is a key target for the development of anti-HCV drugs. Here we report on the identification of novel allosteric inhibitors of HCV NS5B through a combination of structure-based virtual screening and in vitro NS5B inhibition assays.

International Conference "Inhibitors of Protein Kinases 2012"

On 24-27 August 2012 Otava participated in 7^th International Conference "Inhibitors of Protein Kinases" (IPK'2012) that took place in Warsaw, Poland. Like previous Conferences in this series, the 7^th IPK was devoted to the fundamental properties of protein kinases, which special emphasis on the development of selective inhibitors of these enzymes. Galyna's poster presentation was entitled "In silico design and in vitro evaluation of novel ASK1 inhibitors" and described novel compounds inhibiting protein kinase ASK1.

New publication: Electrochemical screening of the indole/quinolone derivatives as potential protein kinase CK2 inhibitors

Otava has published new scientific paper on CK2 inhibitors. 

Abstract: An electrochemical method based on the bioorganometallic Fc-ATP cosubstrate for kinase-catalyzed phosphorylation reactions was used for monitoring casein kinase 2 (CK2) phosphorylations in the absence and presence of five indole/quinolone-based potential inhibitors. 

New publication: Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2

Otava has published new scientific paper on CK2 inhibitors. 

Abstract: Serine/threonine protein kinase CK2 controls vast variety of fundamental processes in cell life; however, despite long period of study, its functional role is not completely determined. CK2 has a significant pathogenic potential and its activity is strictly associated with the development of various kinds of disorders. There are a growing number of facts that inhibitors of CK2 could be used as pharmaceutical agents for the cancer treatment, viral infections, and inflammatory diseases. 

Collaboration with John Paul II Catholic University of Lublin

Otava has started collaboration with Department of Molecular Biology of John Paul II Catholic University of Lublin. In terms of the collaboration, Otava supplied it's CK2 inhibitors for detailed evaluation in vitro tests within the research facilities of the University.

The new class of potent ATP-competitive inhibitors of the human protein kinase CK2 has been identified

A novel series of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids has been synthesized and tested in vitro towards human protein kinase CK2. 

VI International Conference on Protein Kinase CK2

Scientists from Otava, Ltd. participated in the VI International Conference on Protein Kinase CK2 (07-10 September, 2010, Cologne, Germany). Their oral presentation was addressed on the CK2 inhibitors development.

III International Symposium Methods and Applications of Computational Chemistry

Scientists from Otava, Ltd. has attended the ІІІ International Symposium Methods and Applications of Computational Chemistry (June 28 - July 2, 2009, Odessa, Ukraine). At the Conference they gave a talk on “Computer-aided design of novel protein kinase CK2 inhibitors”.

OTAVA offers Protein Kinase inhibitors set (KIS^_TM) for kinase-associated research. KIS^_TM contains 17 known kinase inhibitors. A majority of these inhibitors are available from our company only.

Kyiv, 29th of October 2008 – OTAVA Ltd., a leading Ukrainian fluorescent probe company, and SIGMA-ALDRICH, world-wide known Life Science and High Technology company, jointly released novel fluorescent stain Nancy-520 for dsDNA visualization on agarose gels.